KR20050024873A - Novel streptomyces sp. producing antibacterial and antifungal agent - Google Patents

Abstract

PURPOSE: An antibacterial and antifungal agent producing Streptomyces sp. is provided, which Streptomyces sp. has a wide range of antimicrobial activity against human pathogenic bacteria and plant pathogenic bacteria and does not cause side effects by residence and accumulation of toxicity in human body. CONSTITUTION: The Streptomyces sp.(KACC 91017) producing an antibacterial and antifungal agent against human pathogenic bacteria and plant pathogenic bacteria is provided, wherein the human pathogenic bacterium is selected from Staphylococcus aureus, Staphylococcus epidermidis, Micrococcus luteus, Mycobactereium tuberculosis, Mycobacterium fortuitum, Mycobacterium abscessus and Candida albicans; and the plant pathogenic bacterium is selected from Streptomyces scabiei, Streptomyces acidiscabies and Streptomyces turgidiscabies.

Description

NOVEL STREPTOMYCES SP. Strain of Streptomyces genus that produces antifungal and antibacterial substances. PRODUCING ANTIBACTERIAL AND ANTIFUNGAL AGENT}

[TECHNICAL FIELD OF THE INVENTION]

The present invention relates to a strain of Streptomyces genus that produces antifungal and antibacterial substances, and more particularly, to produce antibacterial substances having antimicrobial activity against human pathogenic bacteria and plant diseases, human body toxicity and residual and accumulated It relates to an environmentally friendly microbial preparation that does not cause side effects.

[Private Technology]

Antibiotics were observed in 1940 based on penicillin, which was discovered by Fleming in 1929 after antagonism between microorganisms was observed by Tyndall, and the actinomycin was introduced in Streptomyces antibioticus in 1940. Streptomyces was isolated from Streptomyces griseus and used as a treatment for pulmonary tuberculosis. Since the discovery of streptomycin, many researchers have discovered many kinds of antibiotics from Streptomyces spp., And recently, researches on producing antibiotics using recombinant technology have been conducted. Actinomycetes, including the genus Streptomyces, have become an important microorganism in industrial and medical terms as an antibiotic producing bacterium.

Strains of the genus Streptomyces have a wide variety of biological activities, including various secondary metabolites. In particular, about two-thirds of the 100,000 bioactive substances detected by microorganisms were found in Streptomyces spp., About 13% in bacteria and 23% in fungi. These bacteria occupy a very high proportion in the search for various bioactive substances.

Recently, the development of new antibiotics is urgently required due to the frequent appearance of resistant bacteria against antibiotics. In particular, Staphylococcus aureus is the most important pathogen among Gram-positive bacteria, and it is also resistant to methicillin or even vancomycin, which is considered to be the last therapeutic agent, so the development of new antibiotics is very urgent. . Tuberculosis-inducing mycobacterium tuberculosis ( M. tuberculosis ) has also emerged as a multi-drug resistant tuberculosis bacterium, proving the need for new anti-tuberculosis drugs.

Candida albican, a fungus that causes candidiasis in the mucous membrane of the human body, is known to cause vaginitis and vulvitis in skin diseases or in women.However, tissues other than skin in immunosuppressive conditions caused by the use of adrenal steroids or antitumor drugs It also acts as an opportunistic infection and may cause systemic disease in immunocompromised patients such as people with acquired immunodeficiency syndrome.

Accordingly, there is a need for the development of new strains that produce antibiotics exhibiting strong antimicrobial activity against various pathogenic microorganisms.

On the other hand, antibiotics as metabolites produced from living organisms have antifungal activity only against pathogens, have little effect on humans, livestock, plants, etc., and do not remain in the environment. Therefore, antibiotics produced from living organisms are emerging as an alternative to organic synthetic pesticides due to the advantages of being environmentally friendly and free of residual toxicity.

In particular, in the case of potatoes, potato beetle disease is frequently caused by Streptomyces scabies and Streptomyces acidisscabies . Potato scallops cause economic losses to potato farmers because of poor growth of potatoes, but research on microbial agents that can effectively control them is insufficient.

Therefore, an object of the present invention is to provide a novel actinomycetes having antimicrobial activity against pathogenic bacteria of the human body.

In addition, an object of the present invention is to provide a novel actinomycetes having antimicrobial activity against potato beetle.

It is also an object of the present invention to provide an environmentally friendly antimicrobial composition that does not have residual toxicity and does not cause side effects.

In order to achieve the above object, the present invention provides a strain Streptomyces sp. (KACC 91017) that produces antibacterial substances against human pathogenic bacteria and plant diseases.

The present invention also provides an antimicrobial composition comprising one or more selected from the group consisting of Streptomyces sp. Strain (KACC 91017), its culture solution and its culture filtrate.

Hereinafter, the present invention will be described in detail.

The present invention relates to a strain of Streptomyces sp., Which produces an antibacterial substance having antibacterial activity against human pathogenic bacteria and plant diseases, and a microbial preparation using the strain.

Streptomyces genus strain of the present invention is a strain isolated from soil samples, it was identified by the morphological characteristics (Fig. 1) and 16S rDNA sequencing (SEQ ID NO: 3). When strains of Streptomyces genus were analyzed for phylogenetic location, they formed an independent branch belonging to Streptomyces in the phylogenetic tree but having a sequence difference of at least 1% from other Streptomyces strains (FIG. 2 and 3). That is, the strain Streptomyces genus of the present invention is a new strain belonging to the genus Streptomyces.

The strain Streptomyces genus of the present invention is named Streptomyces genus 2-15, and was deposited on December 5, 2002 at the Agricultural Microorganisms Preservation Center located in Gwonseon-gu, Suwon-si, Gyeonggi-do, South Korea received the accession number KACC 91017.

Streptomyces genus 2-15 of the present invention can be grown in actinomycetes culture medium, the culture conditions are cancer culture for 7 to 14 days at 25 to 30 ℃. Representative culture medium is Bennett's medium.

Streptomyces spp. 2-15 produces antimicrobial agents with antimicrobial activity against human pathogenic bacteria and plant diseases. In particular, the body pathogenic bacteria is Staphylococcus Cocos spp, Mycoplasma spp, and bacteria and fungi, preferably genus Streptomyces 2-15 Coconut Staphylococcus aureus (Staphylococcus aureus), Staphylococcus epi Cocos terminal display (Staphylococcus epidermidis , Micrococcus luteus , Mycobacterium tuberculosis , Mycobacterium fortuitum , Mycobacterium abscessus and Candida albicans Produces antimicrobial agents against Candida albicans . The plant pests include Streptomyces scabiei , Streptomyces acdiscabies and Streptomyces turgidiscabies , Streptomyces genus 2-15 The antimicrobial material produced from the above also exhibits antimicrobial activity against the three plant diseases.

Antimicrobials produced from Streptomyces genus 2-15 can be secreted extracellularly. Accordingly, the present invention provides an antimicrobial composition comprising at least one selected from the group consisting of Streptomyces genus 2-15, its culture solution and its culture filtrate as an active ingredient. The content of the active ingredient in the antimicrobial composition may be appropriately selected in consideration of the purpose of use and the method of use, for example, may be 0.01% by weight or more. In addition, the antimicrobial composition may further include an additive commonly used.

The culture solution may be obtained by culturing Streptomyces genus 2-15 on a liquid culture medium at 25 to 30 ° C. for 7 to 14 days, and may be included in the antimicrobial composition in a liquid or dried solid phase.

The culture filtrate is a supernatant from which the cells are removed from the culture solution, and can be obtained by centrifugation or filtration. The culture filtrate may be included in the antimicrobial composition in liquid form or in a dried solid phase.

The antimicrobial composition of the present invention may further comprise a carrier according to the use, purpose and method in addition to the above-mentioned effective ingredient. Since the antimicrobial composition may be used as a food additive, a medicament or a microbial pesticide, a conventional carrier suitable for the above use may be included.

When the antimicrobial composition is a food additive, it is used for the purpose of antimicrobial and preservation of food, the formulation thereof may be a liquid, granule powder, aerosol, emulsion or pill. The amount of the food additive used may be properly adjusted according to the type of food and the method of use. For example, the food additive may be used in an amount of 0.01% by weight or more.

When the antimicrobial composition is a medicament, the antimicrobial composition is used for oral or parenteral use, and a pharmacologically acceptable excipient is used as a carrier. The formulation of the antimicrobial composition is appropriately adjusted according to the condition of the patient and the method of use. Examples of the formulation include liquid, granule, powder, syrup, aerosol, extract, ointment, liquid extract, emulsion, suspension, premises, It can be used as a tablet, an injection, a capsule, a cream, or a pill. The dosage of the antimicrobial composition may be 10 to 1000 mg per day, but is not limited thereto.

When the antimicrobial composition is a microbial pesticide, the formulation of the antimicrobial composition may be a powder, granules, liquids, fumigations, or fumigants, depending on the method of use, and may include an extender or electrodeposition agent commonly used in pesticides as a carrier. The method of using the antimicrobial composition is a method of inoculating the soil or directly inoculating the target crop. The amount and timing of use should be adjusted according to the crops applied. Applicable crops are crops which are diseased by Streptomyces Scavies, Streptomyces escidica Vyce or Streptomyces tergidis cavies, and the representative crop is potato. The three strains inhabit soil and cause potato beetle disease mainly at harvest. Therefore, potato beetle disease is preferably sprayed on the soil prior to planting the antimicrobial composition of the present invention, or periodically to the crop or soil during the harvesting period, in particular during the tuber forming period. The spray amount of the antimicrobial composition can be used to be appropriately adjusted according to the degree of disease and fertilization time, but can be used to fertilize the soil or crops sufficiently. At this time, it can be used diluted with water or other fertilizer, pesticide additives. The antimicrobial composition is most preferably applied by adopting a known method according to the type of crop applied.

The genus Streptomyces genus 2-15 of the present invention is an environmentally friendly microbial agent that produces antibacterial substances having antimicrobial activity against human pathogenic bacteria and plant diseases, and does not cause side effects due to human toxicity and residual and accumulated.

Hereinafter, examples of the present invention will be described. The following examples are only for illustrating the present invention and the present invention is not limited to the following examples.

Example 1 Isolation and Identification of Strains

1-1. Strain isolate

Collected soil samples from Jeju Island, Bennett agar medium (Benntt's agar medium: Glucose 10 g, Yeast extract 1 g, Bactptone 2 g, Beef extract 1 g, Agar 15-20 g, distilled water 1L, vitamin (thimine) -HCl, riboflavin, niacin, pyridoxin-HCl, inositol and Ca-pantothenate, aminobenzoic acid 0.5 mg and biotin 0.25 mg), Cycloheximide 50 ppm Nalidixic acid 10 ppm, pH 7.2), Staphylococcus aureus, Candida albicans And one of the best strains showing strong antibacterial activity in common to Streptomyces scaviai.

1-2. Strain Identification

Identification of the strains selected above was carried out as follows.

end. Morphological characteristics

The selected strains were inoculated in Bennett medium and incubated at 28 ° C. for 7 days, and the colors of the strains and the medium were observed by using a color difference meter (CR-300 Chroma, Minolta Camera Co. Ltd., Japan). 1 is a photograph of colonies and cultured cultures of selected strains, and shows a process of observing color using a colorimetric colorimeter. The selected strains formed dark dark red (10.0RV 2.1, C 0.5) colonies, and the secondary metabolite produced by the selected strains diffused into the medium, showing a dark orange color (2.0YR V 3.1, C 5.9). .

I. 16S rDNA Sequencing

In order to confirm the phylogenetic location of the selected strains, 1519 bp sequences corresponding to 98% or more of the 16S rDNA sequences were analyzed.

16S rDNA fragments from the selected strains were amplified by PCR with primer sets of SEQ ID NOs: 1 and 2, and then purified by amplification products, TOPO TA Cloning  It was inserted into a kit (Invitrogen) and transformed into E. coli. After extracting the plasmid from transformed E. coli, the nucleotide sequence was analyzed using an Applied Biosystems model 373A automatic sequencer and a kit (BigDye Terminator Cycle Sequencing kit, Perkin-Elmer Applied Biosystems).

16S rDNA of the selected strain is shown in SEQ ID NO: 3, and homology was analyzed using the Blast program of the GenBank. Genbank's BLAST program was used. As a result, the selected strain showed the highest homology of 98% with VTT E-99-1326 (GenBank No. 429390) of Streptomyces genus, and more than 1% of all the previously analyzed fungi on 16S rDNA homology. The strain of the present invention was found to be a novel Streptomyces genus strain because of the sequence variation.

All. 16S rDNA sequence tree construction

To analyze the phylogenetic location, 35 strains of previously analyzed Streptomyces strain and 13 strains of Kitasatospora and 1 strain of Micromonospora, which were systematically similar to the Streptomyces strain, were included. The base sequence of 16S rDNA of 49 strains was taken from the gene bank and compared with the base sequence of 16S rDNA 1450 bp of the selected strain analyzed in the present invention.

The 16S rDNA sequences of all 50 strains were multi-aligned using the multiple alignment algorithm of the Megaalign package (Window version 3.12e; DNASTAR, Madison, Wis). The phylogenetic tree was completed by Neighbor-Joining (MEGA version 2.1). In order to evaluate the topology of the phylogenetic tree, 1000 times of bootstrap was performed using the micromonospora genus AJ560637 as an outgroup.

Fig. 2 is a generated phylogenetic tree based on the 16S rDNA gene nucleotide sequence of the selected strain of the present invention. Although the strain of the present invention belongs to Streptomyces on the phylogenetic tree, all of the other strains formed an independent branch having a sequence difference of 1% or more. That is, the phylogenetic strain of the present invention can be confirmed by the phylogenetic tree is a new strain belonging to the genus Streptomyces.

la. Cell Wall Fatty Acid Analysis

In order to identify species and genus levels of the selected strains, the fatty acids in the cell walls of the strains were analyzed by MIDI automated microbial identification system (MIS) and gas chromatography (GC). In addition, the database of MIS ACTIN1 library (version 3.8) was used.

The result is shown by chromatography in FIG. The novel strain of Streptomyces sp. Of the present invention was identified through fatty acid component analysis, and all of them matched the existing database to less than 0.4. In particular, S. aureofaciens and the highest homology index (similarity indexes) 0.363, which is within the range of 0.400 recognized as the same species on the MIS ACTIN1 library, the genus Streptomyces of the present invention It can be seen that the selection strain is a new strain.

Based on the above identification results, the selected strain of the present invention was named Streptomyces genus 2-15, which was deposited on December 5, 2002 to the Agricultural Microorganisms Conservation Center located in Gwonseon-gu, Suwon-si, Gyeonggi-do, Korea accession number KACC 91017 was granted.

Example 2 Validation of Antimicrobial Activity of Streptomyces spp. 2-15

2-1. Culture of Streptomyces genus 2-15

Streptomyces spp. 2-15 was inoculated in a Bennett solid medium and cultured at 28 ° C. for 7 days to obtain one colony, which was Bennett liquid medium (Yeast extract 1g / L, Beef extract 1g / L, Tryptone 2 g / l, Glycerol 10 g / l, pH 7.2). The culture was performed by stirring at 180 rpm for 2 weeks at 28 ° C. under dark conditions. The culture was centrifuged at 10,000 rpm for 30 minutes at 4 ° C to separate the supernatant, which was used for antagonist separation.

2-2. Antimicrobial Activity Assay for Human Pathogenic Bacteria

The antimicrobial activity of the fungi belonging to four groups, Gram-positive bacteria, Gram-negative bacteria, Mycobacterium spp. And fungi, was identified.

Gram-positive bacteria include Staphylococcus aureus, Staphylococcus epithemis, Micrococcus luteus, Gram-negative bacteria, E. coli, Shigella disgenteri, Pseudomonas aeruginosa, and mycobacteria. Mycobacterium tuberculosis, Mycobacterium fortuitum, Mycobacterium ephesus and fungi were Candida albicans, and growth inhibition experiments were carried out with a total of 10 species.

The Gram-positive bacteria, Gram-negative bacteria, and fungi were all used in the group of strains stored in the Department of Microbiology, College of Medicine, Seoul National University, and all three species belonging to the mycobacteria were used standard strains stored in the tuberculosis research institute.

Plate media used for growth inhibition experiments were nutrient-positive agar (Beef extract 3 g / l, peptone 5 g / l, agar 15 g / l) for Gram-positive bacteria, Gram-negative bacteria and fungi, and Middlebrook for strains of Mycobacterium spp. 7H10 agar medium (7H10 agar (Difco): 21 g / l, OADC supplement 10 ml / l) was used.

40 μl of the culture supernatant of Streptomyces genus 2-15 was placed on a plate medium, dried for 30 minutes, and sterilized by exposure to ultraviolet light for about 5 minutes. Here, 50 μl of each pathogenic bacterial culture solution was added to distilled water containing 3% agar prepared in a 50 ° C. incubator, mixed well, and then aliquoted to the plate medium and incubated in the incubator. The cultures were different depending on the strains. A total of 9 strains, including Gram-negative bacteria, Gram-positive bacteria, fungi, Mycobacterium potitumum and Mycobacterium epsisus, were incubated at 37 ° C. for 3 days. Leeum tuberculosis was incubated for 30 days at 37 ℃ because of the slow growth rate. After the culture, the growth inhibition ring (transparent ring) formed on the plate medium was confirmed to confirm the antimicrobial activity of Streptomyces genus 2-15.

The diameter of growth inhibition ring for each strain was measured and shown in Table 1 below.

Test target bacteria Activity level Gram-positive bacteria Staphylococcus aureus +++ Staphylocokos Epitermidis ++ Micrococos Luteus ++++ Gram-negative bacteria From Lycian collie N Shigella Disgenterie N Pseudomonas Eruzinosa N Mycobacterium Mycobacterium tubeculosis ATCC 27294 ++++ Mycobacterium Potitumum ATCC 6841 +++ Mycobacterium Absesus CAP97E-03 +++ Fungus Candida albicans ++++ * Activity degree ++++: 25 mm or more, +++: 21-25 mm, ++: 16-20 mm, +: 10-15 mm, N: 0 mm

 In Table 1, Streptomyces spp. 2-15 of the present invention is Mycobacterium including Staphylococcus aureus, a major causative agent of hospital infection, Mycobacterium tuberculosis, Gram-positive bacteria, and a major causative agent of tuberculosis. It showed strong antibacterial activity against the genus strain and Candida albicans, the main fungus causing human infection.

4 is a growth inhibitory ring photograph showing antimicrobial activity against Candida albicans of Streptomyces genus 2-15, where A is the supernatant of 2-15 culture medium of Streptomyces and B is Streptomyces genus 2- 15 The supernatant of the culture was used after proteinase K (PK) or heat treatment (100 DEG C, 5 minutes).

In Figure 4 it can be seen that the antifungal substance produced by Streptomyces genus 2-15 is not a protein component, and is very stable to heat.

2-3. Antimicrobial Activity Assay against Potato Beetle Pathogenic Bacteria

As the pathogens of potato beetle pathogenic bacteria which are plant diseases, Streptomyces scavies, Streptomyces essidica Viece and Streptomyces tergidis cavies were used as test subjects. All the strains are ATCC standard strains possessed by Jeju Agricultural Research Institute, and were cultured in Bennett's medium.

Growth inhibition experiment was carried out in the same manner as above, potato beetle pathogenic bacteria were incubated for 3 days at 28 ℃, respectively. The experimental results are shown in Table 2 below.

Test target bacteria Activity level Potato beetle disease Streptomyces Skabiei ++++ Streptomyces Esidicascars +++ Streptomyces turjidiscabies +++ * Activity degree ++++: 25 mm or more, +++: 21-25 mm, ++: 16-20 mm, +: 10-15 mm, N: 0 mm

In Table 2, Streptomyces genus 2-15 of the present invention was confirmed to exhibit a strong antimicrobial activity against potato beetle pathogenic bacteria.

Figure 5 is a growth inhibitory picture showing the antimicrobial activity against Streptomyces Skabei of Streptomyces genus 2-15, A is the case of using the supernatant of 2-15 culture medium of Streptomyces and B is Streptomyces spp. The supernatant of 2-15 culture solution is used after proteinase K (PK) or heat treatment (100 ° C, 5 minutes). As a result, it can be seen that the antibacterial substance produced by the genus Streptomyces 2-15 is not a protein component and is very stable to heat.

As described above, Streptomyces genus 2-15 (KACC 91017) of the present invention has a wide range of antibacterial activity against various types of human pathogenic bacteria and potato beetle pathogenic bacteria, and does not cause side effects due to human toxicity and residual and accumulated It is an environmentally friendly microbial agent.

Figure 1 is a photo of the culture Streptomyces genus 2-15 strain cultured in Bennett agar medium.

Figure 2 is a phylogenetic tree based on the 16S rDNA gene of 2-15 strain Streptomyces genus of the present invention.

Figure 3 is a result of analyzing the fatty acid component of the strain Streptomyces genus 2-15 of the present invention.

Figure 4 is a growth inhibition ring photograph showing the antimicrobial activity against Candida albicans of Streptomyces genus 2-15.

5 is a growth inhibitory photograph showing the antimicrobial activity against Streptomyces scabeyd of Streptomyces genus 2-15.

<110> LIVER RESEARCH FOUNDATION OF KOREA <120> NOVEL STREPTOMYCES SP. PRODUCING ANTIBACTERIAL AND ANTIFUNGAL AGENT <130> dpp20032312kr <160> 3 <170> KopatentIn 1.71 <210> 1 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 1 gagagtttga tcctggctca g 21 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 2 aaggaggtga tccagccgca 20 <210> 3 <211> 1519 <212> DNA <213> 16S rDNA gene sequences of Streptomyces sp. 2-15 <400> 3 agagttttat cctggctcag gacgaacgct ggcggcgtgc ttaacacatg caagtcgaac 60 gatgaagccc ttcggggtgg attagtggcg aacgggtgag taacacgtgg gcaatctgcc 120 cttcactctg ggacaagccc tggaaacggg gtctaatacc ggatacgacc cggaagcgca 180 tgcttctggg tggaaagctc cggcggtgaa ggatgagccc gcggcctatc agcttgttgg 240 tggggtaatg gcctaccaag gcgacgacgg gtagccggcc tgagagggcg accggccaca 300 ctgggactga gacacggccc agactcctac gggaggcagc agtggggaat attgcacaat 360 gggcgaaagc ctgatgcagc gacgccgcgt gagggatgac ggccttcggg ttgtaaacct 420 ctttcagcag ggaagaagcg aaagtgacgg tacctgcaga agaagcgccg gctaactacg 480 tgccagcagc cgcggtaata cgtagggcgc aagcgttgtc cggaattatt gggcgtaaag 540 agctcgtagg cggcttgtca cgtcggatgt gaaagcccgg ggcttaaccc cgggtctgca 600 ttcgatacgg gctagctaga gtgtggtagg ggagatcgga attcctggtg tagcggtgaa 660 atgcgcagat atcaggagga acaccggtgg cgaaggcgga tctctgggcc attactgacg 720 ctgaggagcg aaagcgtggg gagcgaacag gattagatac cctggtagtc cacgccgtaa 780 acgttgggaa ctaggtgttg gcgacattcc acgtcgtcgg tgccgcagct aacgcattaa 840 gttccccgcc tggggagtac ggccgcaagg ctaaaactca aaggaattga cgggggcccg 900 cacaagcagc ggagcatgtg gcttaattcg acgcaacgcg aagaacctta ccaaggcttg 960 acatataccg gaaacggcca gagatggtcg cccccttgtg gtcggtatac aggtggtgca 1020 tggctgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga gcgcaaccct 1080 tgttctgtgt tgccagcatg cccttcgggg tgatggggac tcacaggaga ctgccggggt 1140 caactcggag gaaggtgggg acgacgtcaa gtcatcatgc cccttatgtc ttgggctgca 1200 cacgtgctac aatggccggt acaatgagct gcgatgccgt gaggcggagc gaatctcaaa 1260 aagccggtct cagttcggat tggggtctgc aactcgaccc catgaagtcg gagttgctag 1320 taatcgcaga tcagcattgc tgcggtgaat acgttcccgg gccttgtaca caccgcccgt 1380 cacgtcacga aagtcggtaa cacccgaagc cggtggccca accccttgtg ggagggagct 1440 gtcgcaaggt gggactggcg attgggacga agtcgtaaca aggtagccgt accggaaggt 1500 gcggctggat cacctcctt 1519

Claims (5)

Streptomyces sp. Strain (KACC 91017), which produces antimicrobial agents against human pathogenic bacteria and plant diseases. The method of claim 1, The human pathogenic bacteria Staphylococcus aureus , Staphylococcus epidermidis , Staphylococcus epidermidis , Micrococcus luteus , Mycobacterium tuberculosis , Mycobacterium tuberculosis Streptomyces genus strain (KACC 91017) selected from the group consisting of Mycobacterium fortuitum , Mycobacterium abscessus and Candida albicans . The method of claim 1, The plant disease bacterium Streptomyces Scar ratio A (Streptomyces scabiei), CD Scar bieseu (Streptomyces acdiscabies) and genus Streptomyces strain selected from the group consisting of a discharge car bieseu (Streptomyces turgidiscabies) Streptomyces burst in Streptomyces (KACC 91017). Claim 1 Streptomyces genus strain (KACC 91017), an antimicrobial composition comprising at least one selected from the group consisting of its culture solution and its culture filtrate. The antimicrobial composition of claim 4 wherein the antimicrobial composition is a food additive, a medicament or a microbial pesticide.